Document is current
Any future updates will be listed below
-
Authors
Puik, Jisce R.
Poels, Thomas T.
Hooijer, Gerrit K. J.
Cysouw, Matthijs C. F.
Verheij, Joanne
Wilmink, Johanna W.
Giovannetti, Elisa
Kazemier, Geert
Sarasqueta, Arantza Farina
Oprea-Lager, Daniela E.
Swijnenburg, Rutger-Jan https://orcid.org/0000-0002-3980-4634
- License Information
-
More Information
Article History
Received: 7 March 2024
Accepted: 2 January 2025
First Online: 14 January 2025
Declarations
:
: The PANSCAN-2 study was a non-blinded, prospective phase I/II study that was conducted at the Amsterdam UMC between 2021 and 2023. The study protocol and study-related procedures were designed and conducted in full compliance with the ethical guidelines of the Declaration of Helsinki and International Conference on Harmonization (ICH) guidelines on Good Clinical Practice, as well as the Dutch national and local regulations. The study protocol was approved by the Medical Ethical Board of the Amsterdam UMC, location VUmc (NL73356.029.20). The trial is registered as PANSCAN-2 in the European Clinical Trials Database (EudraCT number: 2020–002185-14). Before study participation, written informed consent was obtained from each individual patient.
: Written informed consent was obtained from each individual patient.
: The authors declare no competing interests.
